CD19 and neoplasm: The first clinical trial (NCT03097770) designed to evaluate the effect of an autologous, bispecific anti-CD19/anti-CD20 CAR-T in R/R B-cell lymphoma has shown its safety and ability to induce a durable antitumor response, possibly due to a superior immune-synapsis stability and the mitigation of antigen-negative escape by tumor cells (80).